Repros Therapeutics (RPRX) Shares are Up 19.77%

Repros Therapeutics (RPRX) : Traders are bullish on Repros Therapeutics (RPRX) as it has outperformed the S&P 500 by a wide margin of 24.31% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 19.85%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 19.77% in the last 1 week, and is up 28.49% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 23.18% and the 50-Day Moving Average is 19.65%. Repros Therapeutics Inc. has dropped 10.55% during the last 3-month period . Year-to-Date the stock performance stands at 75.21%.


Repros Therapeutics (NASDAQ:RPRX): stock turned positive on Friday. Though the stock opened at $1.85, the bulls momentum made the stock top out at $2.2 level for the day. The stock recorded a low of $1.8075 and closed the trading day at $2.12, in the green by 17.78%. The total traded volume for the day was 1,865,918. The stock had closed at $1.8 in the previous days trading.

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Companys product candidates include Androxal and Proellex. The Companys primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men. The Companys Proellex product candidate for female reproductive health is a chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.